Nautilus Biotechnology (NASDAQ:NAUT) Announces Earnings Results

Nautilus Biotechnology (NASDAQ:NAUT) released its quarterly earnings data on Monday. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02, FiscalAI reports. The business had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.21 million.

Nautilus Biotechnology Trading Up 3.4%

Shares of NASDAQ:NAUT opened at $2.52 on Tuesday. The business’s 50 day moving average is $1.42 and its 200-day moving average is $2.09. Nautilus Biotechnology has a 1-year low of $0.84 and a 1-year high of $4.31. The firm has a market capitalization of $321.05 million, a PE ratio of -5.74 and a beta of 0.73.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Zacks Research raised Nautilus Biotechnology to a “hold” rating in a research note on Wednesday, September 30th. Roth Capital initiated coverage on shares of Nautilus Biotechnology in a research note on Tuesday, September 29th. They issued a “buy” rating and a $3.50 target price for the company. Weiss Ratings downgraded Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. Finally, Leerink Partners initiated coverage on shares of Nautilus Biotechnology in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $4.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Nautilus Biotechnology presently has a consensus rating of “Moderate Buy” and an average target price of $3.83.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc is a biotechnology company developing technologies for large-scale protein analysis, also known as proteomics. Its goal is to enable researchers to identify and quantify proteins more comprehensively, helping advance drug discovery, biological research and the development of precision medicine.

The company’s principal offering is the Nautilus Proteome Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software.